)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Soligenix
Soligenix (SNGX) investor relations material
Soligenix Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Net loss narrowed in Q3 and 9M 2026 as R&D spending fell after the HyBryte development program was terminated; a vendor-liability settlement gain also reduced losses.
Development focus includes SGX302 for psoriasis, SGX945 for Behçet's disease, SGX942 for oral mucositis, and government-funded vaccine programs.
Financial highlights
Revenue was $0 for Q3 and 9M 2026 and the comparable 2025 periods.
Q3 2026 net loss was $1.12M vs. $2.53M in Q3 2025; 9M net loss was $5.93M vs. $8.18M.
R&D expense fell to $357K in Q3 2026 from $1.58M and to $3.11M for 9M from $5.20M; G&A was $1.02M and $3.25M, respectively.
Q3 and 9M 2026 included gains on extinguishment of vendor liabilities of $180K and $238K, respectively.
Outlook and guidance
Cash runway is expected to support operations, development and obligations into Q2 2028, based on the current budget, cash outflows and cash on hand.
Planned R&D spending for the next 12 months is $1.6M, with the substantial majority allocated to Specialized BioTherapeutics; no grant reimbursements are anticipated to offset that segment's R&D.
Priorities include advancing SGX302 and SGX945, seeking a partner for SGX942's next Phase 3 study, and pursuing government grants, partnerships and strategic alternatives.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Soligenix
- Net loss narrowed on lower R&D costs; focus shifts to SGX945 and vaccines amid going concern risk.SNGX
Q2 2026 - Key votes include board elections, reverse stock split, and share authorization increase.SNGXProxy filing
- Proxy seeks approval for reverse split, share increase, and highlights governance and ESG focus.SNGXProxy filing
- Reverse split and share increase proposed to maintain Nasdaq listing and enable future growth.SNGXProxy filing
- Proxy seeks approval for reverse split, share increase, director elections, and executive pay.SNGXProxy filing
- Net loss narrowed, FLASH2 trial halted, focus shifts to pipeline amid funding risks.SNGXQ1 2026
- Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGXCorporate presentation
- Net loss rose to $11.1M in 2025, with liquidity concerns and new capital needed for continued operations.SNGXQ4 2025
- Late-stage rare disease therapies and vaccines show strong clinical and commercial promise.SNGXCorporate presentation
Next Soligenix earnings date
Q4 202618 Mar, 2027
Soligenix
Next Soligenix earnings date
Q4 202618 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Soligenix Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases and biodefense indications. The company works on therapies for inflammatory conditions, oncology, and infectious diseases, with both proprietary drug candidates and government-supported programs. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.